Next-Generation Cancer Immunotherapy
A special issue of Immuno (ISSN 2673-5601). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 407
Special Issue Editor
Interests: onco-immunology; cancer immunotherapy; immunopathology; CAR-T cell; tumor microenvironment; cancer vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has become the standard in many advanced cancers. Recently, it has been applied to neoadjuvant and adjuvant settings in surgically resectable early cancers. In addition, various combinations and modalities are being developed in pre-clinical and clinical studies. This Special Issue focuses on the rationale and strategy of next-generation cancer immunotherapy based on basic and clinical immunology, especially modulation of the tumor microenvironment, antigen-specific immunotherapy, and biomarkers for precision medicine.
Prof. Dr. Toshihiko Torigoe
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- tumor microenvironment
- cancer vaccine
- CAR-T cell
- neoantigen
- biomarker
- stress response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
